News releases

Please be advised that the information posted was accurate at the time of posting, but may be superseded by subsequent news releases.

To automatically receive future news releases, please go to the News subscription service page.

[2014] - 2013 - 2012 - 2011 - 2010 - 2009 - 2008 - 2007 - 2006 - 2005 - 2004 - 2003 - 2002

(click to view the full text)

September 2, 2014
Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York
August 7, 2014
Aeterna Zentaris Reports Second Quarter 2014 Financial and Operating Results
August 6, 2014
Aeterna Zentaris to Present at Upcoming Canaccord Genuity 34th Annual Global Growth Conference in Boston
August 5, 2014
Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market
July 31, 2014
Aeterna Zentaris to Announce Second Quarter 2014 Financial and Operating Results on August 7, 2014
June 11, 2014
Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto
June 10, 2014
Aeterna Zentaris Implements Global Resources Optimization Program as Part of its Transition into a Commercially Operating Specialty Biopharmaceutical Company
June 2, 2014
Aeterna Zentaris: Poster Presented at ASCO Meeting on the Design of the Current ZoptEC Phase 3 Trial in Endometrial Cancer
May 22, 2014
Aeterna Zentaris: Poster to be Presented on the Design of Current ZoptEC Phase 3 Trial in Endometrial Cancer with Zoptarelin Doxorubicin at ASCO
May 12, 2014
Aeterna Zentaris Announces Board of Directors Leadership Change and Election of Directors at Annual Meeting of Shareholders
May 9, 2014
Aeterna Zentaris Announces At the Market Issuance Program
May 8, 2014
Aeterna Zentaris Reports First Quarter 2014 Financial and Operating Results
May 5, 2014
Aeterna Zentaris Selects Charleston, S.C. as New Location for its North American Business and Global Commercial Operations
April 30, 2014
Aeterna Zentaris to Announce First Quarter 2014 Financial and Operating Results on May 8, 2014 and Hold Annual Shareholders Meeting on May 9, 2014
April 9, 2014
Aeterna Zentaris: Poster Presentation at AACR Meeting Provides Rationale for New Therapeutic Opportunities in Oncology with Erk Inhibitors
April 1, 2014
Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego
March 28, 2014
Aeterna Zentaris Announces Effectiveness of $50 Million Shelf Registration Statement for “At-the-Market” Common Share Issuance Programs
March 20, 2014
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2013 Financial and Operating Results
March 12, 2014
Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2013 Financial and Operating Results on March 20, 2014
February 4, 2014
Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer
February 3, 2014
Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin and Disorazol Z Conjugates at Upcoming International Symposium on GnRH
January 14, 2014
Aeterna Zentaris Announces Closing of US$13.2 Million Public Offering of Common Shares and Warrants
January 9, 2014
Aeterna Zentaris Announces Pricing of US$13.2 Million Public Offering of Common Shares and Warrants
January 8, 2014
Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants
January 6, 2014
Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by the FDA
January 3, 2014
Aeterna Zentaris Appoints Dr. Richard Sachse as Chief Scientific Officer